.png)
GlobalLux RX Announces Successful Pivotal Bioequivalence Study for Differentiated Enzalutamide Tablets, Strengthening Its Position in Patient-Centric Oncology Formulation
Riga, Latvia – July 2026 – GlobalLux SIA, operating under GloballuxRx brand is a pharmaceutical development company focused on differentiated and value-added generic medicines, today announced the successful completion of the pivotal bioequivalence study for its Enzalutamide Film-Coated Tablets 160mg.
The successful study represents a major development milestone for GloballuxRx’s differentiated Enzalutamide program and supports the planned readiness for DCP submission in July 2026 using Austria as RMS.
Enzalutamide is one of the world’s leading oncology therapies and remains a strategically important product in the treatment of prostate cancer. GloballuxRx has developed a differentiated tablet formulation designed to address one of the most practical challenges in long-term cancer therapy: daily pill burden and swallowability.
GloballuxRx’s Enzalutamide is among only few that will be available in EU markter to include 40 mg, 80 mg, and 160 mg strengths for the European market and has been developed using an advanced formulation and product design approach focused on improving the patient experience.
The differentiated portfolio is designed to offer:
· approximately 40% smaller 40 mg and 80 mg tablets compared with originator and generic tablets;
· a 160 mg tablet almost comparable in size to the reference 80 mg tablet;
· reduction in daily pill burden from four tablets to one once-daily tablet;
· a patient-centric design aligned with increasing regulatory focus on swallowing difficulties and choking risks associated with oral medicines.
Across oncology, formulation science, particle engineering, and nanotechnology-enabled drug delivery are increasingly being used to improve how medicines perform and how patients experience treatment. Global Lux RX believes this trend is particularly relevant for established oncology molecules where differentiation can be created not by changing the active substance, but by improving the dosage form, usability, and commercial readiness of the product.
“This milestone confirms Global Lux RX’s ability to apply nano-formulation know-how to high-value oncology assets,” said Pravin Patil, Head of R&D and Partnerships of GloballuxRx. “Our Enzalutamide program is not simply another generic development. It is a differentiated, patient-centric tablet portfolio designed around real-world treatment challenges, regulatory timing, and commercial partner needs.”
With the pivotal bioequivalence study successfully completed and the DCP submission in July 2026, GloballuxRx believes the program is entering a critical partnering window.
XTANDI® generated approximately US$5.2 billion in annual global sales, making Enzalutamide one of the most commercially significant oncology therapies worldwide. For partners seeking timely access to the European Enzalutamide opportunity, GloballuxRx offers a differentiated, three-strength, submission-ready asset with a design-around strategy and clear patient-centric positioning.
The company believes that the window for securing differentiated Enzalutamide opportunities worldwide is narrowing as more companies move toward standard tablet development. GloballuxRx’s combination of successful pivotal BE results, dossier readiness, complete strength coverage, and differentiated tablet design creates a compelling opportunity for partners seeking to enter the market with a product that is not only bioequivalent, but commercially and clinically better positioned.
Contact maxim.vlasenko@globalluxrx.comRiga, Latvia – July 2026 – GlobalLux SIA, operating under GloballuxRx brand is a pharmaceutical development company focused on differentiated and value-added generic medicines, today announced the successful completion of the pivotal bioequivalence study for its Enzalutamide Film-Coated Tablets 160mg.
The successful study represents a major development milestone for GloballuxRx’s differentiated Enzalutamide program and supports the planned readiness for DCP submission in July 2026 using Austria as RMS.
Enzalutamide is one of the world’s leading oncology therapies and remains a strategically important product in the treatment of prostate cancer. GloballuxRx has developed a differentiated tablet formulation designed to address one of the most practical challenges in long-term cancer therapy: daily pill burden and swallowability.
GloballuxRx’s Enzalutamide is among only few that will be available in EU markter to include 40 mg, 80 mg, and 160 mg strengths for the European market and has been developed using an advanced formulation and product design approach focused on improving the patient experience.
The differentiated portfolio is designed to offer:
· approximately 40% smaller 40 mg and 80 mg tablets compared with originator and generic tablets;
· a 160 mg tablet almost comparable in size to the reference 80 mg tablet;
· reduction in daily pill burden from four tablets to one once-daily tablet;
· a patient-centric design aligned with increasing regulatory focus on swallowing difficulties and choking risks associated with oral medicines.
Across oncology, formulation science, particle engineering, and nanotechnology-enabled drug delivery are increasingly being used to improve how medicines perform and how patients experience treatment. Global Lux RX believes this trend is particularly relevant for established oncology molecules where differentiation can be created not by changing the active substance, but by improving the dosage form, usability, and commercial readiness of the product.
“This milestone confirms Global Lux RX’s ability to apply nano-formulation know-how to high-value oncology assets,” said Pravin Patil, Head of R&D and Partnerships of GloballuxRx. “Our Enzalutamide program is not simply another generic development. It is a differentiated, patient-centric tablet portfolio designed around real-world treatment challenges, regulatory timing, and commercial partner needs.”
With the pivotal bioequivalence study successfully completed and the DCP submission in July 2026, GloballuxRx believes the program is entering a critical partnering window.
XTANDI® generated approximately US$5.2 billion in annual global sales, making Enzalutamide one of the most commercially significant oncology therapies worldwide. For partners seeking timely access to the European Enzalutamide opportunity, GloballuxRx offers a differentiated, three-strength, submission-ready asset with a design-around strategy and clear patient-centric positioning.
The company believes that the window for securing differentiated Enzalutamide opportunities worldwide is narrowing as more companies move toward standard tablet development. GloballuxRx’s combination of successful pivotal BE results, dossier readiness, complete strength coverage, and differentiated tablet design creates a compelling opportunity for partners seeking to enter the market with a product that is not only bioequivalent, but commercially and clinically better positioned.
